BC Innovations | Dec 19, 2019
Distillery Therapeutics

SLC5A12 inhibition for rheumatoid arthritis

DISEASE CATEGORY: Autoimmune disease INDICATION: Rheumatoid arthritis (RA) Inhibiting the lactate transporter SLC5A12 could treat RA. In 87 patients with early RA, high levels of SLC5A12 RNA expression in the synovium was associated with increased...
BioCentury | Dec 7, 2019
Product Development

U.S. biosimilars glass--half full or half empty?

Ten years after the U.S. created a pathway for biosimilars--and four and a half years after the first FDA approval--a few manufacturers have demonstrated that they can overcome the technical, regulatory and commercial barriers to...
BC Extra | Nov 6, 2019
Company News

Biogen expanding biosimilars deal for eye therapies, anti-TNFs

As it continues to rely on biosimilars as a growth driver, Biogen has expanded its deal with Samsung Bioepis to include two new ocular biosimilars in certain major markets, as well as rights in China...
BC Extra | Oct 16, 2019
Financial News

Oct. 15 Financial Quick Takes: Phathom, Galera, J&J earnings, RTW Investments, Azitra, MaveriX

Phathom, Galera move toward listings  Phathom Pharmaceuticals Inc. proposed terms for an IPO on NASDAQ. The GI company proposed to sell 7.9 million shares at $18-$20; at the mid-point, it would raise $150.1 million at...
BC Extra | Jul 19, 2019
Company News

July 19 Company Quick Takes: First biosimilars of Avastin, Herceptin launched; plus Gilenya, Celltrion-Nan Fung and Celgene

Amgen, Allergan launch pair of biosimilars  Amgen Inc. (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) launched Mvasi bevacizumab-awwb and Kanjinti trastuzumab-anns in the U.S.; they are the first biosimilars of Avastin bevacizumab and Herceptin trastuzumab available in...
BioCentury | Apr 19, 2019
Politics, Policy & Law

Thin U.S. biosimilars market fuels proposals to regulate biologics prices

Frustration over the failure of biosimilars to slash the costs of decades-old biologics has prompted a group of policy analysts to suggest abandoning attempts to copy biologics. Because the sole purpose of biosimilars is to...
BioCentury | Mar 28, 2019
Product Development

Contracting practices limiting U.S. biosimilars uptake

The U.S. biosimilars market lags Europe’s and won’t catch up until physicians understand and become comfortable with the concept of similarity, Sheila Frame, who heads up Sandoz’s North American biosimilars business, told BioCentury. To create...
BC Extra | Feb 26, 2019
Politics & Policy

Pharma CEOs present united front - except on biosimilars

Seven pharma leaders expressed strong support for eliminating rebates to PBMs and insurance companies, shifting from volume- to value-based reimbursement, and reducing out-of-pocket costs for drugs in testimony Tuesday to the Senate Finance Committee. The...
BC Extra | Dec 12, 2018
Company News

Management tracks: Merck creates new commercial roles to follow Schechter's exit

Merck & Co. Inc. (NYSE:MRK) said President of Global Human Health Adam Schechter will step down at the end of the year. The company will restructure his former position into two new roles effective Jan....
BC Extra | Dec 4, 2018
Politics & Policy

Biosimilar makers back Pfizer in call to end misleading brand marketing

A group of biosimilar manufacturers including Pfizer Inc. (NYSE:PFE) urged FDA to produce supplemental guidance clarifying how to comply with existing law when communicating about biosimilars. The Biosimilars Forum sent its plea in a letter...
Items per page:
1 - 10 of 830